While CD20 is a reliable marker for B-cells, there are diagnostic challenges. For instance, some B-cell lymphomas may lose CD20 expression, especially after treatment with anti-CD20 therapies. This loss can complicate the diagnosis and monitoring of these diseases. Therefore, it is crucial to use a panel of markers and not rely solely on CD20 for diagnostics.
